United States: Life Sciences, Biotechnology & Nanotechnology

The opening quarter of 2026 brought a noticeable cooling in mid-market life sciences venture activity, with deal volume dropping significantly from prior periods.

The U.S. Department of War has designated WuXi AppTec, a major contract development and manufacturing organization partnering with numerous U.S. biotechnology and pharmaceutical companies, as a "Chinese military company" under Section 1260H.

On June 4, 2026, Teva Pharmaceutical Industries Ltd. (“Teva”) announced the launch of its aflibercept biosimilar, AHZANTIVE®, in Europe.

Lupin has secured FDA approval for RANLUSPEC, a ranibizumab biosimilar to Genentech's LUCENTIS, marking a significant development in the treatment of neovascular age-related macular degeneration and retinal vascular disorders. This approval establishes RANLUSPEC as the only interchangeable biosimilar ranibizumab available in both vials and pre-filled syringes in the United States, representing Lupin's second biosimilar to receive FDA authorization.

The life sciences sector continues to be a growing area of interest for national security controls, as U.S. pharmaceutical companies have increasingly partnered with Chinese firms for development, manufacturing, and licensing arrangements.

As a result, morality and ethical exclusions have moved from largely theoretical concepts to a practical issue that can determine the fate of a patent application.

The FDA is taking a dual approach to artificial intelligence in the pharmaceutical sector, issuing compliance warnings for manufacturing while simultaneously encouraging AI innovation in clinical trials.

This monthly newsletter examines significant legal trends and landmark cases in tort law, including the Sixth Circuit's reversal of class certification, FDA's dual approach to AI regulation in pharmaceuticals, Minnesota's upcoming PFAS ban, and the Supreme Court's expansive interpretation of federal officer removal jurisdiction. These developments carry strategic implications for businesses navigating complex litigation and regulatory compliance across multiple industries.

Life sciences companies with promising science and strong management can still face severe financial distress due to failed trials, regulatory delays, or collapsed financing.